tiprankstipranks
RVL Pharmaceuticals (RVLPQ)
OTHER OTC:RVLPQ
US Market

RVL Pharmaceuticals (RVLPQ) Price & Analysis

311 Followers

RVLPQ Stock Chart & Stats

<$0.01
>-$0.01(-99.00%)
At close: 4:00 PM EST
<$0.01
>-$0.01(-99.00%)

RVLPQ FAQ

What was RVL Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is RVL Pharmaceuticals’s market cap?
RVL Pharmaceuticals’s market cap is $111.00.
    When is RVL Pharmaceuticals’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were RVL Pharmaceuticals’s earnings last quarter?
    Currently, no data Available
    Is RVL Pharmaceuticals overvalued?
    According to Wall Street analysts RVL Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does RVL Pharmaceuticals pay dividends?
      RVL Pharmaceuticals does not currently pay dividends.
      What is RVL Pharmaceuticals’s EPS estimate?
      RVL Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does RVL Pharmaceuticals have?
      RVL Pharmaceuticals has 111,406,044 shares outstanding.
        What happened to RVL Pharmaceuticals’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of RVL Pharmaceuticals?
        Currently, no hedge funds are holding shares in RVLPQ
        What is the TipRanks Smart Score and how is it calculated?
        Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

          Company Description

          RVL Pharmaceuticals

          RVL Pharmaceuticals plc operates as a specialized drug company, dedicated to innovating and marketing pharmaceutical solutions for patient groups with unmet needs in the ophthalmic and medical aesthetics domains. The firm's activities extend across the United States, Argentina, and Hungary. Its principal commercial offering is Upneeq (RVL-1201), an ophthalmic solution containing oxymetazoline hydrochloride, specifically formulated to address acquired blepharoptosis, or drooping eyelids, in adults. The company, formerly known as Osmotica Pharmaceuticals plc, officially rebranded to RVL Pharmaceuticals plc in January 2022. Its corporate headquarters are situated in Bridgewater, New Jersey.

          RVL Pharmaceuticals (RVLPQ) Earnings & Revenues

          Similar Stocks
          Company
          Price & Change
          Follow
          Biodexa Pharmaceuticals
          Scinai Immunotherapeutics
          PainReform
          Dermata Therapeutics

          Ownership Overview

          13.86%86.14%
          Insiders
          Mutual Funds
          13.86% Other Institutional Investors
          86.14% Public Companies and
          Individual Investors

          Options Prices

          Currently, No data available
          ---
          Popular Stocks